Rheumatoid Arthritis Clinical Studies

You have full text access to this OnlineOpen article

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

  1. Johan Askling1,†,*,
  2. Ronald F. van Vollenhoven1,†,
  3. Fredrik Granath1,‡,
  4. Pauline Raaschou1,
  5. C. Michael Fored1,
  6. Eva Baecklund2,§,
  7. Christina Dackhammar3,
  8. Nils Feltelius4,
  9. Lars Cöster5,
  10. Pierre Geborek6,
  11. Lennart T. Jacobsson7,
  12. Staffan Lindblad1,
  13. Solbritt Rantapää-Dahlqvist8,
  14. Tore Saxne6,
  15. Lars Klareskog1,¶

Article first published online: 29 OCT 2009

DOI: 10.1002/art.24941

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 11, pages 3180–3189, November 2009

Additional Information

How to Cite

Askling, J., van Vollenhoven, R. F., Granath, F., Raaschou, P., Fored, C. M., Baecklund, E., Dackhammar, C., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., Rantapää-Dahlqvist, S., Saxne, T. and Klareskog, L. (2009), Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?. Arthritis & Rheumatism, 60: 3180–3189. doi: 10.1002/art.24941

Author Information

  1. 1

    Karolinska University Hospital at Solna and Karolinska Institutet, Stockholm, Sweden

  2. 2

    Uppsala University Hospital, Uppsala, Sweden

  3. 3

    Sahlgrenska University Hospital, Gothenburg, Sweden

  4. 4

    Karolinska University Hospital at Solna and Karolinska Institutet, Stockholm, Sweden, and Medical Products Agency, Uppsala, Sweden

  5. 5

    Linköping University Hospital, Linköping, Sweden

  6. 6

    Lund University Hospital, Lund, Sweden

  7. 7

    Malmö University Hospital, Malmö, Sweden

  8. 8

    Norrland University Hospital, Umeå, Sweden

  1. †

    Drs. Askling and von Vollenhoven have each received consulting fees, speaking fees, and/or honoraria from Wyeth, Schering-Plough, and Abbott (less than $10,000 each).

  2. ‡

    Dr. Granath owns stock or stock options in AstraZeneca.

  3. §

    Dr. Baecklund has received consulting fees, speaking fees, and/or honoraria from Schering-Plough.

  4. Dr. Klareskog has received research grants from Schering-Plough, Wyeth, Abbott, Roche, Bristol-Myers Squibb, and AstraZeneca.

*Clinical Epidemiology Unit T2, Department of Medicine Solna, Karolinska University Hospital at Solna, 171 76 Stockholm, Sweden

Publication History

  1. Issue published online: 29 OCT 2009
  2. Article first published online: 29 OCT 2009
  3. Manuscript Accepted: 11 JUL 2009
  4. Manuscript Received: 20 FEB 2009

Funded by

  • Swedish Cancer Society
  • Stockholm County Council
  • ARTIS
  • Swedish Biologics Register
  • Wyeth-Ayerst
  • Schering-Plough
  • Abbott Immunology
  • Roche
  • Bristol-Myers Squibb
  • The South Swedish Anti-TNF Register has received funding from the King Gustav V
  • Österlund
  • Kock Foundations
  • Reumatikerförbundet
  • Swedish National Board of Health and Welfare

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (99K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hemda Rosenblum, Howard Amital, Anti-TNF therapy: Safety aspects of taking the risk, Autoimmunity Reviews, 2011, 10, 9, 563

    CrossRef

  2. 2
    A. Ludwiczuk, A. Saha, T. Kuzuhara, Y. Asakawa, Bioactivity guided isolation of anticancer constituents from leaves of Alnus sieboldiana (Betulaceae), Phytomedicine, 2011, 18, 6, 491

    CrossRef

  3. 3
    Gabriella Nagy, Katalin Lukács, Ágnes Sziray, Katalin Fazekas, Ágnes Florián, László Tamási, Zsuzsánna Károlyi, Biológiai terápia során észlelt mellékhatások – különös tekintettel a bőrgyógyászati szövődményekre, Orvosi Hetilap, 2011, 152, 6, 212

    CrossRef

  4. 4
    Loreto Carmona, Lydia Abasolo, Miguel A. Descalzo, Beatriz Pérez-Zafrilla, Agustí Sellas, Francisco de Abajo, Juan J. Gomez-Reino, Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists, Seminars in Arthritis and Rheumatism, 2011, 41, 1, 71

    CrossRef

  5. 5
    Johan Askling, Kyle Fahrbach, Beth Nordstrom, Susan Ross, Christopher H. Schmid, Deborah Symmons, Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data, Pharmacoepidemiology and Drug Safety, 2011, 20, 2
    Direct Link:
  6. 6
    Nicola J. Gullick, David L. Scott, Co-morbidities in established rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 2011, 25, 4, 469

    CrossRef

  7. 7
    Emilio Martín Mola, Blanca Hernández, Miriam García-Arias, José María Álvaro-Gracia, Alejandro Balsa, Juan Gómez-Reino, José L. Marenco de la Fuente, Víctor Martínez-Taboada, José Andrés Román Ivorra, Raimon Sanmartí, Consensus on the use of Rituximab in Rheumatoid Arthritis. A document with evidence based recommendations, Reumatolog ía Cl ínica (English Edition), 2011, 7, 1, 30

    CrossRef

  8. 8
    Pauline Raaschou, Julia F. Simard, Martin Neovius, Johan Askling, Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents, Arthritis & Rheumatism, 2011, 63, 7
    Direct Link:
  9. 9
    Denis Poddubnyy, Martin Rudwaleit, Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Expert Opinion on Drug Safety, 2011, 10, 4, 655

    CrossRef

  10. 10
    Frank Bachmann, Georgios Kokolakis, Wolfram Sterry, Sandra Philipp, Etanercept overview of clinical experience in the treatment of psoriasis and psoriatic arthritis, International Journal of Clinical Rheumatology, 2011, 6, 2, 135

    CrossRef

  11. 11
    Laurent Peyrin–Biroulet, Kiarash Khosrotehrani, Fabrice Carrat, Anne–Marie Bouvier, Jean–Baptiste Chevaux, Tabassome Simon, Frank Carbonnel, Jean–Frédéric Colombel, Jean–Louis Dupas, Philippe Godeberge, Jean–Pierre Hugot, Marc Lémann, Stéphane Nahon, Jean–Marc Sabaté, Gilbert Tucat, Laurent Beaugerie, Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease, Gastroenterology, 2011, 141, 5, 1621

    CrossRef

  12. 12
    Ithamar Heber Brinkman, Mart AFJ van de Laar, Tim L Jansen, Eric N van Roon, The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis, Expert Opinion on Drug Safety, 2011, 10, 5, 715

    CrossRef

  13. 13
    Thao Pham, Hervé Bachelez, Jean-Marie Berthelot, Jacques Blacher, Yoram Bouhnik, Pascal Claudepierre, Arnaud Constantin, Bruno Fautrel, Philippe Gaudin, Vincent Goëb, Laure Gossec, Philippe Goupille, Séverine Guillaume-Czitrom, Eric Hachulla, Isabelle Huet, Denis Jullien, Odile Launay, Marc Lemann, Jean-Francis Maillefert, Jean-Pierre Marolleau, Valérie Martinez, Charles Masson, Jacques Morel, Luc Mouthon, Stanislas Pol, Xavier Puéchal, Pascal Richette, Alain Saraux, Thierry Schaeverbeke, Martin Soubrier, Anne Sudre, Tu-Anh Tran, Manuelle Viguier, Olivier Vittecoq, Daniel Wendling, Xavier Mariette, Jean Sibilia, TNF alpha antagonist therapy and safety monitoring, Joint Bone Spine, 2011, 78, 15

    CrossRef

  14. 14
    J. D. Alves, A. Marinho, M. J. Serra, Tocilizumab: is there life beyond anti-TNF blockade?, International Journal of Clinical Practice, 2011, 65, 4
    Direct Link:
  15. 15
    Enrique Jorquera Barquero, Tratamientos biológicos y cáncer, Piel, 2011, 26, 5, 231

    CrossRef

  16. 16
    G. Horneff, T. Hospach, G. Dannecker, D. Föll, J.P. Haas, H.J. Girschick, H.I. Huppertz, R. Keitzer, H.J. Laws, H. Michels, K. Minden, R. Trauzeddel, Aktualisierte Stellungnahme der GKJR zur Meldung der FDA über Fälle von Malignomen bei Anti-TNF-behandelten Patienten vom 04.08.2009, Zeitschrift für Rheumatologie, 2010, 69, 6, 561

    CrossRef

  17. 17
    Karen B. Onel, Kenan Onel, Anti–tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders, Arthritis Care & Research, 2010, 62, 7
    Direct Link:
  18. 18
    Manfred Kopf, Martin F. Bachmann, Benjamin J. Marsland, Averting inflammation by targeting the cytokine environment, Nature Reviews Drug Discovery, 2010, 9, 9, 703

    CrossRef

  19. 19
    Huseyin TE Ozer, Zeynep Ozbalkan, Clinical efficacy of TNF-α inhibitors: an update, International Journal of Clinical Rheumatology, 2010, 5, 1, 101

    CrossRef

  20. 20
    A. Strangfeld, K. Hyrich, J. Askling, E. Arkema, R. Davies, J. Listing, M. Neovius, J. Simard, D. Symmons, K. Watson, A. Zink, Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers, Rheumatology, 2010, 50, 1, 146

    CrossRef

  21. 21
    Martin Soubrier, Sylvain Mathieu, Sarah Payet, Jean-Jacques Dubost, Jean-Michel Ristori, Elderly-onset rheumatoid arthritis, Joint Bone Spine, 2010, 77, 4, 290

    CrossRef

  22. 22
    Christopher W. Espelin, Arthur Goldsipe, Peter K. Sorger, Douglas A. Lauffenburger, David de Graaf, Bart S. Hendriks, Elevated GM-CSF and IL-1β levels compromise the ability of p38 MAPK inhibitors to modulate TNFα levels in the human monocytic/macrophage U937 cell line, Molecular BioSystems, 2010, 6, 10, 1956

    CrossRef

  23. 23
    W. Kievit, J. Fransen, E. M. M. Adang, A. A. den Broeder, H. J. Bernelot Moens, H. Visser, M. A. F. van de Laar, P. L. C. M. van Riel, Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register, Rheumatology, 2010, 50, 1, 196

    CrossRef

  24. 24
    M. Elaine Husni, Philip J. Mease, Managing Comorbid Disease in Patients with Psoriatic Arthritis, Current Rheumatology Reports, 2010, 12, 4, 281

    CrossRef

  25. 25
    Danielle Antin-Ozerkis, Janine Evans, Ami Rubinowitz, Robert J. Homer, Richard A. Matthay, Pulmonary Manifestations of Rheumatoid Arthritis, Clinics in Chest Medicine, 2010, 31, 3, 451

    CrossRef

  26. 26
    X. Mariette, J.-E. Gottenberg, P. Ravaud, B. Combe, Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries, Rheumatology, 2010, 50, 1, 222

    CrossRef

  27. 27
    H. Bastian, G.-R. Burmester, Spielt TNF in der Pathogenese von soliden Tumoren eine Rolle?, Zeitschrift für Rheumatologie, 2010, 69, 6, 483

    CrossRef

  28. 28
    J. Askling, The risk of malignancies in RA patients treated with biologics, Zeitschrift für Rheumatologie, 2010, 69, 9, 774

    CrossRef

  29. 29
    G. Horneff, T. Hospach, G. Dannecker, D. Föll, J.P. Haas, H. Girschick, H.I. Huppertz, R. Keitzer, H.J. Laws, K. Minden, R. Trauzeddel, H. Michels, Therapie mit TNFα-Inhibitoren, Monatsschrift Kinderheilkunde, 2010, 158, 4, 372

    CrossRef

  30. 30
    Anja Strangfeld, Angela Zink, Therapy: Assessing cancer risk of cytokine inhibitors in RA, Nature Reviews Rheumatology, 2010, 6, 3, 126

    CrossRef

  31. 31
    Joel M. Kremer, Jeffrey Greenberg, Interpreting registry-derived drug studies: Does societal context matter?, Arthritis & Rheumatism, 2009, 60, 11
    Direct Link:
View Full Article (HTML) Get PDF (99K)